AstraZeneca PLC's recent Form 6-K reveals Non-Executive Director Karen Knudsen's purchase of 1,400 ADSs, reflecting confidence in the company's future. Key insights on compliance and market sentiment.
Explore Centessa Pharmaceuticals PLC's latest 8-K report, revealing crucial stock details and financial data. Essential for investors and analysts in the biotech sector.
Foresight Autonomous Holdings Ltd. updates on ADS offering, increasing maximum price to $11.4M. Legal compliance and investor transparency highlighted in Form 6-K report.
SaverOne's February 2025 Form 6-K highlights a strategic adjustment in share ratios to meet Nasdaq requirements, ensuring compliance and transparency for investors.
This report details SaverOne's amendment to Form 6-K, correcting the ADS ratio to 1-for-13.33 effective Feb 21, 2025, impacting trading on Nasdaq and equity awards.
Discover SaverOne 2014 Ltd.'s amended Form 6-K/A, detailing a reverse stock split to comply with Nasdaq's $1.00 price rule. Effective February 21, 2025.
SaverOne 2014 Ltd. reports a reverse stock split to meet Nasdaq's $1 minimum bid requirement. Effective Feb 21, 2025, 1 ADS will equal 1,200 ordinary shares.
Explore TC BioPharm's recent Form 6-K filing detailing the ADS ratio change, trading impacts, and warrant adjustments, essential for investors and stakeholders.
Explore Evaxion Biotech A/S's latest Form 6-K report detailing capital increases, public offerings, and warrant grants, crucial for investors and stakeholders.
Jianzhi Education Technology Group's American depositary shares fall below $1.00, triggering Nasdaq compliance action. The report details their 180-day plan to regain compliance.
Explore Quoin Pharmaceuticals Ltd.'s latest 8-K report detailing significant events as of January 14, 2025. Discover key insights about their market presence and share structure.
Discover Wing Yip Food Holdings' IPO details including share offerings, proceeds, and regulatory insights in this January 2025 financial report.